Efficacy and Safety of Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma: a Single-center, Single-arm, Phase 2 Trail
Latest Information Update: 04 Oct 2023
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2022 Pooled results from NCT04547088 and NCT04548271 studies, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 16 Sep 2020 New trial record